Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors. (August 2016)

• Record Type: Journal Article
• Authors: Shi, Xiaodong; Lin, Xiaotian; Hu, Rui; Sun, Nan; Hao, Jingru; Gao, Can
• Is Part Of: American journal of Alzheimer's disease & other dementias. Volume 31:Number 5(2016)
• Page Start: 405
• Page End: 412
• Publication Date: 2016-08
• Subjects: Alzheimer's disease -- cholinesterase inhibitors -- NMDA receptor antagonists -- FDA Adverse Event Reporting System (FAERS); Alzheimer's disease -- Periodicals; Dementia -- Periodicals; Alzheimer's disease -- Patients -- Care -- United States -- Periodicals; 616.83
• DOI: 10.1177/1533317515622283
• Languages: English
• ISSNs: 1533-3175

Abstract

Cholinesterase inhibitors (ChEIs), represented by donepezil, rivastigmine, and galantamine, used to be the only approved class of drugs for the treatment of Alzheimer's disease. After the approval of memantine by the Food and Drug Administration (FDA), N -methyl-d -aspartic acid (NMDA) receptor antagonists have been recognized by authorities and broadly used in the treatment of Alzheimer's disease. Along with complementary mechanisms of action, NMDA antagonists and ChEIs differ not only in therapeutic effects but also in adverse reactions, which is an important consideration in clinical drug use. And the number of patients using NMDA antagonists and ChEIs concomitantly has increased, making the matter more complicated. Here we used the FDA Adverse Event Reporting System for statistical analysis, in order to compare the adverse events of memantine and ChEIs. In general, the clinical evidence confirmed the safety advantages of memantine over ChEIs, reiterating the precautions of clinical drug use and the future direction of antidementia drug development.